ImmuCell Corporation(ICCC)Earnings, Financials & Key Ratios
ICCC•NASDAQ
$8.66
$78M mkt cap·Price updated May 6, 2026
AboutImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Show more
- Revenue$26M+51.6%
- EBITDA$1M+134.5%
- Net Income-$2M+62.7%
- EPS (Diluted)-0.26+65.3%
- Gross Margin29.97%+19.1%
- EBITDA Margin3.95%+122.8%
- Operating Margin-6.19%+81.2%
- Net Margin-8.14%+75.4%
- ROE-8.21%+60.6%
- ROIC-3.09%+72.1%
- Debt/Equity0.55-17.8%
- Interest Coverage-2.88
ICCC Key Insights
ImmuCell Corporation (ICCC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓Momentum leader: RS Rating 87 (top 13%)
- ✓Strong 5Y sales CAGR of 14.1%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ICCC Price & Volume
ImmuCell Corporation (ICCC) stock price & volume — 10-year historical chart
Loading chart...
ICCC Growth Metrics
ImmuCell Corporation (ICCC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years13.31%
5 Years14.06%
3 Years11.25%
TTM16.49%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM160.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM152.36%
Return on Capital
10 Years-1.25%
5 Years-5.35%
3 Years-7.9%
Last Year-4.09%
ICCC Peer Comparison
ImmuCell Corporation (ICCC) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PCRX | 931.85M | 23.69 | 148.06 | 3.63% | 1.27% | 1.31% | 0.66 | |
 NEOG | 2B | 9.18 | -1.83 | -3.2% | -68.47% | -28.64% | 0.44 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 ELAN | 13.06B | 26.16 | -55.66 | 6.22% | -4.95% | -3.64% | 0.61 | |
 PETZ | 10.22M | 0.99 | 5.82 | 121.96% | 190.86% | 12.13% | 0.13 | |
 ZTS | 46.95B | 111.22 | 18.48 | 2.28% | 28.23% | 58.23% | 2.85 | |
 IDXX | 46.12B | 579.23 | 44.28 | 10.42% | 24.63% | 70.87% | 0.67 | |
 CHGG | 129.87M | 1.16 | -1.21 | -38.97% | -26.89% | -62.94% | 0.70 |
Compare ICCC vs Peers
ImmuCell Corporation (ICCC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ICCC Income Statement
ImmuCell Corporation (ICCC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 9.54M | 10.43M | 10.99M | 13.72M | 15.34M | 19.24M | 18.57M | 17.47M | 26.49M | 27.77M |
| Revenue Growth % | -6.69% | 9.29% | 5.32% | 24.91% | 11.8% | 25.43% | -3.51% | -5.9% | 51.63% | 16.49% |
| Cost of Goods Sold | 4.12M | 5.21M | 5.79M | 6.98M | 8.48M | 10.59M | 10.92M | 13.08M | 18.55M | 16.4M |
| COGS % of Revenue | 43.2% | 49.95% | 52.72% | 50.89% | 55.27% | 55.02% | 58.81% | 74.84% | 70.03% | - |
| Gross Profit | 5.42M▲ 0% | 5.22M▼ 3.7% | 5.19M▼ 0.5% | 6.74M▲ 29.8% | 6.86M▲ 1.8% | 8.66M▲ 26.1% | 7.65M▼ 11.6% | 4.4M▼ 42.5% | 7.94M▲ 80.6% | 11.37M▲ 0% |
| Gross Margin % | 56.8% | 50.05% | 47.28% | 49.11% | 44.73% | 44.98% | 41.19% | 25.16% | 29.97% | 40.93% |
| Gross Profit Growth % | -13.28% | -3.68% | -0.52% | 29.77% | 1.82% | 26.12% | -11.63% | -42.52% | 80.63% | - |
| Operating Expenses | 4.53M | 5.46M | 7.34M | 7.69M | 8.24M | 8.4M | 9.95M | 10.14M | 9.58M | 9.04M |
| OpEx % of Revenue | 47.47% | 52.38% | 66.82% | 56.07% | 53.73% | 43.64% | 53.58% | 58.06% | 36.16% | - |
| Selling, General & Admin | 3.29M | 3.42M | 3.82M | 4.01M | 3.89M | 4.23M | 5.45M | 5.22M | 5.68M | 5.94M |
| SG&A % of Revenue | 34.43% | 32.76% | 34.81% | 29.19% | 25.35% | 21.98% | 29.37% | 29.89% | 21.45% | - |
| Research & Development | 1.24M | 2.05M | 3.52M | 3.69M | 4.35M | 4.17M | 4.49M | 4.39M | 3.9M | 3.1M |
| R&D % of Revenue | 13.04% | 19.62% | 32.01% | 26.87% | 28.38% | 21.66% | 24.2% | 25.15% | 14.72% | - |
| Other Operating Expenses | -24.85K | 0 | 0 | 0 | 0 | 0 | 0 | 527K | 0 | 0 |
| Operating Income | 890.2K▲ 0% | -243K▼ 127.3% | -1.45M▼ 495.5% | -954K▲ 34.1% | -1.38M▼ 44.7% | 257.38K▲ 118.7% | -2.3M▼ 993.2% | -5.75M▼ 150.0% | -1.64M▲ 71.5% | 2.33M▲ 0% |
| Operating Margin % | 9.33% | -2.33% | -13.17% | -6.95% | -8.99% | 1.34% | -12.38% | -32.9% | -6.19% | 8.39% |
| Operating Income Growth % | -58.06% | -127.3% | -495.47% | 34.07% | -44.65% | 118.65% | -993.21% | -150.03% | 71.47% | - |
| EBITDA | 1.69M | 661.43K | 73.71K | 1.31M | 982.6K | 2.72M | 188.58K | -3.03M | 1.05M | 5.03M |
| EBITDA Margin % | 17.73% | 6.34% | 0.67% | 9.57% | 6.4% | 14.13% | 1.02% | -17.35% | 3.95% | 18.1% |
| EBITDA Growth % | -36.17% | -60.92% | -88.86% | 1681.85% | -25.19% | 176.67% | -93.06% | -1707.29% | 134.54% | 987.61% |
| D&A (Non-Cash Add-back) | 802.38K | 904.43K | 1.52M | 2.27M | 2.36M | 2.46M | 2.49M | 2.72M | 2.69M | 2.7M |
| EBIT | 890.2K | -219.91K | -1.43M | -835.63K | -714.35K | 237.39K | -2.14M | -5.22M | -1.62M | 2.71M |
| Net Interest Income | -107.03K | -201.66K | -413.48K | -313.5K | -385.25K | -295.55K | -195.44K | 0 | -491.02K | -360.16K |
| Interest Income | 54.66K | 16.91K | 14.3K | 118.28K | 27.44K | 18.81K | 153.1K | 0 | 77.7K | 152.47K |
| Interest Expense | 161.7K | 218.57K | 427.78K | 431.79K | 412.69K | 314.36K | 348.54K | 0 | 568.73K | 512.63K |
| Other Income/Expense | -131.88K | -195.63K | -413.48K | -313.59K | 347.88K | -326.51K | -186.81K | -21.89K | -506.41K | 9.31K |
| Pretax Income | 758.32K▲ 0% | -438K▼ 157.8% | -1.86M▼ 324.7% | -1.27M▲ 31.9% | -1.03M▲ 18.6% | -69.13K▲ 93.3% | -2.49M▼ 3496.0% | -5.77M▼ 132.1% | -2.15M▲ 62.8% | 2.34M▲ 0% |
| Pretax Margin % | 7.95% | -4.2% | -16.93% | -9.24% | -6.73% | -0.36% | -13.39% | -33.02% | -8.1% | 8.42% |
| Income Tax | 249.87K | -270K | 462K | 28K | -10K | 9.16K | 8K | 4.63K | 10.06K | 14.3K |
| Effective Tax Rate % | 32.95% | 61.64% | -24.84% | -2.21% | 0.97% | -13.26% | -0.32% | -0.08% | -0.47% | 0.61% |
| Net Income | 508.45K▲ 0% | -168K▼ 133.0% | -2.32M▼ 1282.1% | -1.3M▲ 44.2% | -1.02M▲ 21.1% | -78.29K▲ 92.3% | -2.49M▼ 3085.5% | -5.77M▼ 131.5% | -2.16M▲ 62.7% | 2.32M▲ 0% |
| Net Margin % | 5.33% | -1.61% | -21.14% | -9.44% | -6.66% | -0.41% | -13.43% | -33.05% | -8.14% | 8.37% |
| Net Income Growth % | -58.09% | -133.04% | -1282.14% | 44.19% | 21.14% | 92.34% | -3085.51% | -131.54% | 62.65% | 160.97% |
| Net Income (Continuing) | 508.45K | -168.15K | -2.32M | -1.3M | -1.02M | -78.29K | -2.49M | -5.77M | -2.16M | 2.32M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.12▲ 0% | -0.03▼ 128.3% | -0.42▼ 1138.9% | -0.19▲ 54.8% | -0.14▲ 26.3% | -0.01▲ 92.6% | -0.32▼ 3006.8% | -0.75▼ 134.4% | -0.26▲ 65.3% | 0.26▲ 0% |
| EPS Growth % | -68.42% | -128.25% | -1138.94% | 54.76% | 26.32% | 92.64% | -3006.8% | -134.38% | 65.33% | 152.36% |
| EPS (Basic) | 0.12 | -0.03 | -0.42 | -0.19 | -0.14 | -0.01 | -0.32 | -0.75 | -0.26 | - |
| Diluted Shares Outstanding | 4.34M | 4.95M | 5.49M | 6.82M | 7.21M | 7.59M | 7.75M | 7.75M | 8.17M | 9.05M |
| Basic Shares Outstanding | 4.23M | 4.95M | 5.49M | 6.82M | 7.21M | 7.59M | 7.75M | 7.7M | 8.17M | 9.05M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ICCC Balance Sheet
ImmuCell Corporation (ICCC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 14.35M | 7.51M | 6.42M | 13.19M | 12.16M | 16.26M | 13.99M | 11.47M | 15.04M | 16.83M |
| Cash & Short-Term Investments | 10.62M | 3.8M | 2.52M | 8.77M | 7.95M | 10.19M | 5.79M | 978.74K | 3.76M | 3.89M |
| Cash Only | 5.15M | 3.8M | 2.52M | 6.29M | 7.95M | 10.19M | 5.79M | 978.74K | 3.76M | 3.89M |
| Short-Term Investments | 5.47M | 0 | 0 | 2.48M | 0 | -468 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.14M | 1.49M | 1.43M | 1.68M | 1.86M | 2.72M | 1.8M | 2.19M | 3.81M | 2.61M |
| Days Sales Outstanding | 43.49 | 52.26 | 47.36 | 44.62 | 44.36 | 51.61 | 35.4 | 45.65 | 52.51 | 40.24 |
| Inventory | 2.13M | 2.05M | 2.33M | 2.52M | 2.09M | 3.09M | 6.04M | 7.81M | 7.11M | 9.8M |
| Days Inventory Outstanding | 188.28 | 143.6 | 146.94 | 131.63 | 90.08 | 106.53 | 201.86 | 218.07 | 139.94 | 181.17 |
| Other Current Assets | 333.11K | 0 | 0 | 800 | 800 | 0 | 0 | 39.73K | 0 | 0 |
| Total Non-Current Assets | 10.35M | 26.79M | 26.31M | 25.5M | 28.19M | 28.2M | 30.87M | 32.34M | 30.06M | 28.9M |
| Property, Plant & Equipment | 9.85M | 26.07M | 26.03M | 25.27M | 27.98M | 28M | 30.64M | 32.15M | 29.91M | 28.76M |
| Fixed Asset Turnover | 0.97x | 0.40x | 0.42x | 0.54x | 0.55x | 0.69x | 0.61x | 0.54x | 0.89x | 0.94x |
| Goodwill | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K | 95.56K |
| Intangible Assets | 171.94K | 152.83K | 133.73K | 114.62K | 95.52K | 76.42K | 57.31K | 38.21K | 19.1K | 4.78K |
| Long-Term Investments | 0 | 0 | 40.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 34.26K | 920 | 53.16K | 26.88K | 26.17K | 26.11K | 76.63K | 57.66K | 33.37K | 176.75K |
| Total Assets | 24.7M▲ 0% | 34.3M▲ 38.9% | 32.73M▼ 4.6% | 38.69M▲ 18.2% | 40.35M▲ 4.3% | 44.47M▲ 10.2% | 44.86M▲ 0.9% | 43.81M▼ 2.3% | 45.1M▲ 3.0% | 45.73M▲ 0% |
| Asset Turnover | 0.39x | 0.30x | 0.34x | 0.35x | 0.38x | 0.43x | 0.41x | 0.40x | 0.59x | 0.61x |
| Asset Growth % | 69.15% | 38.88% | -4.57% | 18.21% | 4.29% | 10.2% | 0.89% | -2.35% | 2.95% | 23.43% |
| Total Current Liabilities | 2.06M | 2.06M | 2.57M | 2.5M | 2.21M | 2.53M | 3.07M | 4.2M | 4.41M | 4M |
| Accounts Payable | 1.51M | 580.46K | 603.74K | 572.18K | 602.35K | 745.04K | 790K | 887.73K | 943.64K | 972.14K |
| Days Payables Outstanding | 133.43 | 40.67 | 38.05 | 29.91 | 25.93 | 25.69 | 26.41 | 24.78 | 18.57 | 23.4 |
| Short-Term Debt | 133.27K | 316.63K | 1.34M | 1.27M | 760.34K | 812.21K | 1.04M | 1.43M | 1.5M | 1.67M |
| Deferred Revenue (Current) | 33.86K | 24.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 175.11K | 0 | 0 | 0 | 306.78K | 0 | 370.13K |
| Current Ratio | 6.97x | 3.64x | 2.50x | 5.29x | 5.50x | 6.42x | 4.56x | 2.73x | 3.41x | 3.41x |
| Quick Ratio | 5.94x | 2.64x | 1.59x | 4.28x | 4.55x | 5.20x | 2.59x | 0.87x | 1.80x | 1.80x |
| Cash Conversion Cycle | 98.34 | 155.2 | 156.25 | 146.34 | 108.5 | 132.45 | 210.85 | 238.94 | 173.88 | 198.01 |
| Total Non-Current Liabilities | 2.92M | 8.64M | 8.42M | 7.21M | 9.87M | 9.35M | 11.41M | 14.62M | 13.17M | 11.93M |
| Long-Term Debt | 2.88M | 8.64M | 8.42M | 7.15M | 8.74M | 8.33M | 9.19M | 10.54M | 9.04M | 7.9M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.14M | 1.03M | 2.22M | 4.08M | 4.13M | 16.41M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 37.35K | 996 | 0 | 58.52K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 4.98M | 10.7M | 10.99M | 9.7M | 12.08M | 11.89M | 14.48M | 18.82M | 17.58M | 15.93M |
| Total Debt | 3.01M | 8.96M | 9.77M | 8.42M | 10.73M | 10.27M | 12.48M | 16.69M | 15.1M | 13.61M |
| Net Debt | -2.14M | 5.16M | 7.24M | 2.13M | 2.79M | 89.03K | 6.69M | 15.71M | 11.34M | 9.72M |
| Debt / Equity | 0.15x | 0.38x | 0.45x | 0.29x | 0.38x | 0.32x | 0.41x | 0.67x | 0.55x | 0.55x |
| Debt / EBITDA | 1.78x | 13.54x | 132.49x | 6.41x | 10.92x | 3.78x | 66.18x | - | 14.42x | 2.71x |
| Net Debt / EBITDA | -1.26x | 7.80x | 98.29x | 1.62x | 2.84x | 0.03x | 35.46x | - | 10.83x | 10.83x |
| Interest Coverage | 5.51x | -1.11x | -3.38x | -2.21x | -3.34x | 0.82x | -6.60x | - | -2.88x | 5.28x |
| Total Equity | 19.72M▲ 0% | 23.59M▲ 19.6% | 21.74M▼ 7.8% | 28.99M▲ 33.3% | 28.27M▼ 2.5% | 32.58M▲ 15.3% | 30.38M▼ 6.7% | 24.99M▼ 17.7% | 27.52M▲ 10.1% | 29.8M▲ 0% |
| Equity Growth % | 85.82% | 19.64% | -7.84% | 33.33% | -2.5% | 15.25% | -6.74% | -17.73% | 10.1% | 67.96% |
| Book Value per Share | 4.55 | 4.77 | 3.96 | 4.25 | 3.92 | 4.29 | 3.92 | 3.23 | 3.37 | 3.29 |
| Total Shareholders' Equity | 19.72M | 23.59M | 21.74M | 28.99M | 28.27M | 32.58M | 30.38M | 24.99M | 27.52M | 29.8M |
| Common Stock | 504.48K | 566.26K | 566.26K | 729.9K | 729.9K | 781.42K | 781.42K | 781.42K | 904.24K | 910.56K |
| Retained Earnings | 1.15M | 978.97K | -1.34M | -2.64M | -3.66M | -3.74M | -6.23M | -12.01M | -14.16M | -12.35M |
| Treasury Stock | -431.94K | -407.88K | -204.95K | -188.34K | -175.39K | -158.17K | -147.23K | -138.48K | -138.48K | -130.76K |
| Accumulated OCI | -23.9K | -638 | 30.16K | -43.9K | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ICCC Cash Flow Statement
ImmuCell Corporation (ICCC) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -323.9K | 1.18M | -373.4K | 233.51K | 1.32M | 954.17K | -1.54M | -4.67M | 357.9K | 357.9K |
| Operating CF Margin % | -3.39% | 11.27% | -3.4% | 1.7% | 8.58% | 4.96% | -8.31% | -26.75% | 1.35% | - |
| Operating CF Growth % | -111.17% | 463.02% | -131.76% | 162.54% | 463.39% | -27.47% | -261.8% | -202.76% | 107.66% | 465.94% |
| Net Income | 508.45K | -168.15K | -2.32M | -1.3M | -1.02M | -78.29K | -2.49M | -5.77M | -2.16M | 2.32M |
| Depreciation & Amortization | 802.38K | 904.43K | 1.52M | 2.27M | 2.35M | 2.46M | 2.49M | 2.72M | 2.69M | 2.71M |
| Stock-Based Compensation | 67.4K | 199.78K | 344.02K | 313.14K | 253.13K | 144.31K | 266.24K | 368.87K | 326K | 260.95K |
| Deferred Taxes | 236.29K | -284.81K | 462.31K | 24.68K | -14.63K | 30.96K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 37.51K | -8.36K | -681.44K | 19.45K | -780.35K | 18.56K | 28.8K | 260.82K | -91.76K | -231.04K |
| Working Capital Changes | -1.98M | 532.92K | 302.66K | -1.1M | 532.26K | -1.62M | -1.83M | -2.27M | -406.52K | -3.07M |
| Change in Receivables | -277.52K | -330.31K | 411.72K | -704.87K | -159.64K | -897.43K | 935.63K | 0 | -1.59M | -246.85K |
| Change in Inventory | -1.14M | 77.17K | -281.94K | -186.59K | 425.74K | -997.46K | -2.95M | 0 | 699.22K | -2.34M |
| Change in Payables | -182.51M | 448.64M | 196.98K | -190.21K | 299.88M | 245.76M | 342 | 157K | 362.61K | -197.04K |
| Cash from Investing | -4.42M | -12.27M | -1.79M | -3.4M | -2.57M | -1.6M | -3.96M | -1.89M | -461.23K | -1.24M |
| Capital Expenditures | -3.59M | -17.76M | -2.03M | -1.39M | -4.07M | -2.61M | -3.98M | -1.89M | -465.73K | -1.27M |
| CapEx % of Revenue | 37.58% | 170.26% | 18.48% | 10.14% | 26.55% | 13.56% | 21.41% | 10.83% | 1.76% | - |
| Acquisitions | -368.22K | -8.66K | -14.08K | -8.91K | 45.6K | 15.29K | 11K | 0 | 0 | 29.23K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 30.94K | 45K | 250K | 450K | 45.6K | 15.29K | 11K | 2.47K | 4.5K | 1.9K |
| Cash from Financing | 8.32M | 9.75M | 889.62K | 6.94M | 1.91M | 3.88M | 1.11M | 1.75M | 2.88M | -668.92K |
| Debt Issued (Net) | -135.84K | 5.99M | 795.33K | -1.36M | 1.96M | -368.27K | 1.1M | 1.81M | -1.47M | -1.47M |
| Equity Issued (Net) | 1000K | 0 | 0 | 0 | 0 | 1000K | 0 | 0 | 1000K | 1.16M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -14.76K | 3.75M | 94.28K | 8.3M | -53.13K | 13.96K | 11.36K | -62.77K | -5.04K | -359.71K |
| Net Change in Cash | 3.58M▲ 0% | -1.35M▼ 137.8% | -1.28M▲ 5.5% | 3.77M▲ 395.2% | 656.64K▼ 82.6% | 3.24M▲ 392.7% | -4.39M▼ 235.8% | -4.81M▼ 9.5% | 2.78M▲ 157.8% | 77.56K▲ 0% |
| Free Cash Flow | -3.91M▲ 0% | -16.58M▼ 324.1% | -2.4M▲ 85.5% | -1.16M▲ 51.8% | -2.76M▼ 138.1% | -1.65M▲ 40.0% | -5.52M▼ 233.6% | -6.57M▼ 19.0% | -107.82K▲ 98.4% | 715.35K▲ 0% |
| FCF Margin % | -40.97% | -158.99% | -21.88% | -8.44% | -17.97% | -8.6% | -29.72% | -37.59% | -0.41% | 2.58% |
| FCF Growth % | -2259.8% | -324.12% | 85.51% | 51.82% | -138.09% | 39.99% | -233.59% | -18.98% | 98.36% | 200.33% |
| FCF per Share | -0.90 | -3.35 | -0.44 | -0.17 | -0.38 | -0.22 | -0.71 | -0.85 | -0.01 | -0.01 |
| FCF Conversion (FCF/Net Income) | -0.64x | -7.00x | 0.16x | -0.18x | -1.29x | -12.19x | 0.62x | 0.81x | -0.17x | 0.31x |
| Interest Paid | 153.09K | 186.54K | 403.54K | 420.96K | 481.41K | 308.68K | 338.52K | 0 | 528.91K | 465.21K |
| Taxes Paid | 123.58K | 6.07K | 4.22K | 3.57K | 4.58K | 5.11K | 4.92K | 0 | 7.29K | -5.91K |
ICCC Key Ratios
ImmuCell Corporation (ICCC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 3.35% | -0.78% | -10.24% | -5.11% | -3.57% | -0.26% | -7.92% | -20.86% | -8.21% | 8% |
| Return on Invested Capital (ROIC) | 4.47% | -0.79% | -3.76% | -2.38% | -3.33% | 0.61% | -4.95% | -11.09% | -3.09% | -3.09% |
| Gross Margin | 56.8% | 50.05% | 47.28% | 49.11% | 44.73% | 44.98% | 41.19% | 25.16% | 29.97% | 40.93% |
| Net Margin | 5.33% | -1.61% | -21.14% | -9.44% | -6.66% | -0.41% | -13.43% | -33.05% | -8.14% | 8.37% |
| Debt / Equity | 0.15x | 0.38x | 0.45x | 0.29x | 0.38x | 0.32x | 0.41x | 0.67x | 0.55x | 0.55x |
| Interest Coverage | 5.51x | -1.11x | -3.38x | -2.21x | -3.34x | 0.82x | -6.60x | - | -2.88x | 5.28x |
| FCF Conversion | -0.64x | -7.00x | 0.16x | -0.18x | -1.29x | -12.19x | 0.62x | 0.81x | -0.17x | 0.31x |
| Revenue Growth | -6.69% | 9.29% | 5.32% | 24.91% | 11.8% | 25.43% | -3.51% | -5.9% | 51.63% | 16.49% |
ICCC Frequently Asked Questions
ImmuCell Corporation (ICCC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ImmuCell Corporation (ICCC) reported $27.8M in revenue for fiscal year 2024. This represents a 467% increase from $4.9M in 1995.
ImmuCell Corporation (ICCC) grew revenue by 51.6% over the past year. This is strong growth.
Yes, ImmuCell Corporation (ICCC) is profitable, generating $2.3M in net income for fiscal year 2024 (-8.1% net margin).
Dividend & Returns
ImmuCell Corporation (ICCC) has a return on equity (ROE) of -8.2%. Negative ROE indicates the company is unprofitable.
ImmuCell Corporation (ICCC) generated $0.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ICCC
ImmuCell Corporation (ICCC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates